骨粗鬆症治療市場：薬剤タイプ別、投与経路別、流通チャネル別、地域別

世界の骨粗鬆症治療市場は、2025年には155億7,000万米ドルと推定され、2032年には210億6,000万米ドルに達すると予測され、2025～2032年にかけてCAGR4.4％で成長すると予測されます。

図.骨粗鬆症治療市場シェア（%）、2025年地域別

骨粗鬆症は、骨量の低下と骨組織の構造的劣化を特徴とする病態であり、骨の脆弱化と骨折リスクの増大につながります。この疾患は、特に高齢者の間で、世界の医療の大きな関心事となっています。平均寿命の伸び、座りがちなライフスタイル、不適切な栄養摂取などの要因が、先進国、発展途上国を問わず骨粗鬆症の有病率上昇に大きく寄与しています。Frontiers誌が発表したデータによると、世界中で2億人以上が骨粗鬆症に苦しんでいます。現在のところ治療法がないため、薬剤療法による生涯管理が骨折の治療と予防に重要な役割を果たしています。世界の骨粗鬆症治療市場は、このアンメットニーズを満たすため、過去数十年にわたって着実な成長を遂げてきました。

市場力学

骨粗鬆症のリスクが高い高齢者の増加が、骨粗鬆症治療の需要を世界的に押し上げると予想されます。国連によると、65歳以上の人口は2050年までに2倍以上に増加すると予想されています。骨粗鬆症のスクリーニングと管理に関する意識の高まり、新製品の発売、リスクのある患者の診断の増加が、市場の成長をさらに促進しています。しかし、ブロックバスター医薬品の特許切れとジェネリック医薬品への嗜好が、引き続き市場の成長を抑制しています。一方、新興国では、医療へのアクセスが向上しているため、大きなビジネス機会が眠っています。

本調査の主要特徴

• 本レポートでは、世界の骨粗鬆症治療市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案マトリクスを解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 世界の骨粗鬆症治療市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
• 主要企業には、Teva Pharmaceutical Industries Ltd.、DAIICHI SANKYO COMPANY, LIMITED、Amgen Inc.、Dr. Reddy's Laboratories Ltd.、Viatris Inc.、Ligand Pharmaceuticals Incorporated、Eli Lilly and Company、Asahi Kasei Corporation、F. Hoffmann-La Roche Ltd.、EffRx Pharmaceuticals SA、Novartis AG、Merck &Co., Inc.、GSK plc.、Pfizer Inc.、Enzene Biosciences、Apotex Inc.などが含まれます。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の骨粗鬆症治療市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。
• 利害関係者は、世界の骨粗鬆症治療市場分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 規制シナリオ
• メーカー収益
• 買収と提携のシナリオ
• 製品の発売/承認
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の骨粗鬆症治療市場-コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の骨粗鬆症治療市場、薬剤タイプ別、2020～2032年（10億米ドル）

• イントロダクション
• ビスフォスフォネート
• カルシトニン、ホルモン療法
• 選択的エストロゲン受容体モジュレーター（SERM）
• 副甲状腺ホルモン関連タンパク質（PTHrP）類似体
• その他

第6章 世界の骨粗鬆症治療市場、投与経路別、2020～2032年（10億米ドル）

• イントロダクション
• 経口
• 注射
• その他

第7章 世界の骨粗鬆症治療市場、流通チャネル別、2020～2032年（10億米ドル）

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の骨粗鬆症治療市場、地域別、2020～2032年（10億米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• 企業プロファイル
  • Teva Pharmaceutical Industries Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Amgen Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Ligand Pharmaceuticals Incorporated
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • F. Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.

第10章 アナリストの推奨事項

• 隆盛と衰退
• 一貫型機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global Osteoporosis Treatment Market is estimated to be valued at USD 15.57 Bn in 2025 and is expected to reach USD 21.06 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.4% from 2025 to 2032.

Figure. Osteoporosis Treatment Market Share (%), By Region 2025

Osteoporosis is a condition characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures. The disease has become a major global healthcare concern, especially among the elderly population. Factors such as increasing life expectancy, sedentary lifestyles, and improper nutrition have contributed significantly to rising prevalence of osteoporosis across both developed and developing nations. According to data published by Frontiers, over 200 million people worldwide suffer from osteoporosis. With no curative treatment currently available, lifelong management through pharmacotherapy plays a crucial role in treatment and prevention of fractures. Global osteoporosis treatment market has witnessed steady growth over the past couple of decades to meet this unmet need.

Market Dynamics:

Growing geriatric population who are at high risk of osteoporosis is expected to boost demand for osteoporosis treatment drugs globally. According to the United Nations, the population aged 65 years and above is expected to more than double by 2050. Rising awareness about osteoporosis screening and management, new product launches, and increasing at-risk patient diagnosis are further propelling the market growth. However, patent expiries of blockbuster drugs and preference for generic drugs continue to restrain the market growth. Meanwhile, significant opportunities lie in emerging economies due to growing accessibility of healthcare.

Key Features of the Study:

• This report provides an in-depth analysis of the global osteoporosis treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global osteoporosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy's Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., Pfizer Inc., Enzene Biosciences, Apotex Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global osteoporosis treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoporosis treatment market.

Detailed Segmentation-

• By Drug Type:
  • Bisphosphonates
  • Calcitonin, Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Others
• By Route of Administration:
  • Oral
  • Injectable
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Teva Pharmaceutical Industries Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Amgen Inc.
  • Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Ligand Pharmaceuticals Incorporated
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Osteoporosis Treatment Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Osteoporosis Treatment Market, By Drug Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Bisphosphonates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Calcitonin, Hormone Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Selective Estrogen Receptor Modulators (SERMs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Osteoporosis Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Osteoporosis Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Osteoporosis Treatment Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • DAIICHI SANKYO COMPANY, LIMITED
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dr. Reddy's Laboratories Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ligand Pharmaceuticals Incorporated
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Asahi Kasei Corporation
  • F. Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact

"